Optimal Timing and Combinations for Carfilzomib in R/R MM: Perspecti…

Icahn School of Medicine at Mount Sinai

J. Richter

De-Escalation of Systemic Therapy For Early Stage Breast Cancer

Icahn School of Medicine at Mount Sinai

A. Tiersten

Pulmonary Hypertension: The Future Is Now

Icahn School of Medicine at Mount Sinai

H. Poor

Classification, Diagnosis and Management of Pulmonary Hypertension: …

Icahn School of Medicine at Mount Sinai

R. Benza

Obstructive Sleep Apnea - Overview and Management

Icahn School of Medicine at Mount Sinai

J. Wang

CAR-T in MM: Best Practices in Patient Selection, Treatment, and Mul…

Icahn School of Medicine at Mount Sinai

A. Rossi

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"

2024 ASCO® Annual Meeting Insights Hub

S. Parekh

ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. Tecli…

2024 ASCO® Annual Meeting Insights Hub

S. Jagannath

Navigating aGVHD Treatment: Integrating Recent Updates in Clinical M…

Icahn School of Medicine at Mount Sinai

J. Ferrara

Leveraging Liquid Biopsy in Lung Cancer

Icahn School of Medicine at Mount Sinai

C. Rolfo

PanRAF Inhibitors in NSCLC

Icahn School of Medicine at Mount Sinai

R. Veluswamy

AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pts Wit…

Icahn School of Medicine at Mount Sinai

S. Jagannath

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

ASH 2023 Insights: "Outcomes After CAR-T in MM Patients With Extrame…

Insights from 2023 ASH Annual Meeting

D. Pan

Multiple Myeloma: Inflammatory Biomarkers and Outcomes CAR T-Cell Th…

Insights from 2023 ASH Annual Meeting

D. Pan

ASH 2023 Insights: "MyDRUG Sub-Protocol Y3 Results - Selinexor, Ixaz…

Insights from 2023 ASH Annual Meeting

J. Richter

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

IMS 2023 Insights: "Highlights From the International Myeloma Societ…

Insights from 2023 IMS Annual Meeting

J. Richter

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Managing the Nonreproductive Comorbidities of Polycycstic Ovary Synd…

Icahn School of Medicine at Mount Sinai

A. Dunaif

Revisiting the Role of Alkylating Agents in Myeloma: Up-to-Date Evid…

Icahn School of Medicine at Mount Sinai

J. Richter

Multiple Myeloma: Adverse Effects of CAR-T

Icahn School of Medicine at Mount Sinai

S. Rajeeve

Leveraging SCLC Subtypes and Other Biomarkers

Icahn School of Medicine at Mount Sinai

F. Hirsch

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Yale Cancer Center

A. Chari

Overview of JAKARTA & JAKARTA2 Trials: Impact of Fedratinib on Splee…

Icahn School of Medicine at Mount Sinai

J. Waksal

What's the Difference? Covalent vs. Non-Covalent BTKis in MCL

Icahn School of Medicine at Mount Sinai

J. Brody

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

Kidney Week 2022: Cell-to-Cell Chats in the Diabetic Kidney Endothel…

Icahn School of Medicine at Mount Sinai

I. Daehn

Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy

Oliver Van Oekelen

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

ASH 2022 Conference Coverage

S. Parekh

SABCS 2022 Predictors of Response to Neoadjuvant Chemo in Breast Can…

SABCS 2022 Conference Coverage

N. Bilani

TKI in the Management of Advanced HCC

Icahn School of Medicine at Mount Sinai

A. Villanueva

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

Triplet Regimens in Early Relapse MM: Evolving Treatment Dynamics

Icahn School of Medicine at Mount Sinai

C. Rodriguez